Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 421-428

  Skarlos, D V ^a,e   Aravantinos, G ^a   Kosmidis, P ^b   Pavlidis, N ^c   Gennatas, K ^d   Beer, M ^e   Mylonakis, N ^b   Makrantonakis, P ^f   Klouvas, G ^c   Karpathios, S ^g   Linardou, H ^a   Konstantaras, C ^f   Fountzilas, G ^f  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b METAXA Cancer Memorial Hospital   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e Hellenic Cooperative Oncology Group   (Greece)

^f AHEPA UNIVERSITY HOSPITAL   (Greece)

^g ALEXANDRA HOSPITAL   (Greece)

Author keywords

Carboplatin based chemotherapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; METOCLOPRAMIDE; ONDANSETRON;

ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 9244230113     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00537-4     Document Type: Article

References (51)

1. Richardson GS, Scully RE, Nikuri N, Nelson JH Jr. Common epithelial cancer of the ovary. N Engl J Med 1985, 312, 415-424.
2. Young RC, Fuks Z, Hoskins WJ. Cancer of the ovary. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology, 3rd Edition. Philadelphia, Lippincott, 1989, 1162-1196.
3. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. J Int Fed Gynecol 1965, 3, 204.
4. Thigpen JT, Vance RB, Laubuth BW. Ovarian carcinoma: the role of chemotherapy. Semin Oncol 1988, 15 (suppl 3), 16-26.
5. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br Med J 1991, 303, 884-893.
6. Trope C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynaecol 1987, 70, 582-586.
7. Manetta A, MacNeill C, Lyter J, et al. Hexamethylmelamine as a single second line agent in ovarian cancer. Gynecol Oncol 1990, 36, 93-96.
8. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987, 5, 1157-1168.
9. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE. Ten-year follow-up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989, 7, 223-229.
10. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. A Gynaecologic Oncology Group study. J Clin Oncol 1989, 7, 457-465.
11. Gruppo Interegionale Cooperativo Oncologico Ginecologia (Bolis G, Marsoni S, Belloni C, et al). Randomized comparison of cisplatin with cyclophosphamide/cisplatin in cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987, 2, 353-359.
12. Ozols RF. New developments of carboplatin in the treatment of ovarian cancer. Semin Oncol 1992, 19 (suppl 2), 85-89.
13. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987, 5, 756-767.
14. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988, 6, 1501-1515.
15. Canetta R, Bragman K, Smaldone L, Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Rev 1988, 15, 17-31.
16. Witshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev 1985, 12, 67-71.
17. Witshaw E, Evans B, Harland S. Phase III randomized trail of cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stage III and IV. Proc Am Soc Clin Oncol 1985, 4, 121.
18. Teeling M, Hayes Y, Fitzmaurice B, Mc Ging P, Carney DN. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer. Semin Oncol 1992, 19 (suppl 2), 102-106.
19. Swenerton KD, Pater JL for the Ovarian Cancer Subcommittee. Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Semin Oncol 1992, 19 (suppl 2), 114-119.
20. Ten Bokkel Huinink WW, Dalesio O, Rodenhuis S, et al. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long term treatment results of a study of the Gynaecological Cancer Co-operative Group of EORTC and experience at the Netherlands Cancer Institute. Semin Oncol 1992, 19 (suppl 2), 99-101.
21. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication no. 48. The Hague, Nijhoff, 1979.
22. Hyrniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990, 8, 1935-1937.
23. Rozencweig M, Martin A, Bellangady M, et al. Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In Bunn PA, Cannetta R, Ozols RF, et al., eds. Carboplatin (JM-8). Current Prospectives and Future Directions. Philadelphia, Saunders, 1990, 175-186.
24. Machin D, Cambell MJ. Statistical Tables for the Design of Clinical Trials. Oxford, Blackwell, 1987, 119.
25. Dixon WJ, Brown MB, Engelman L, Jennrich RI (eds). MBDP Statistical Software Manual. Los Angeles, University of California Press, 1990, 135-144, 145-163, 231-310, 739-768.
26. Woolson RF. Statistical Methods for the Analysis of Biomedical Data. New York, Wiley, 1987, 156-163, 815-886.
27. Karlan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
28. Mantel N. Evaluation of survival data and the two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-170.
29. Breslow NA. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970, 57, 579-594.
30. Tarone R, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977, 64, 156-160.
31. Cox DR. Regresion models and life tables. J R Stat Soc 1972, 34, (series B), 187-220.
32. Cox DR. The Analysis of Binary Data. London, Methuen, 1970.
33. Medical Research Council Gynaecologial Cancer Working Party. An overview in the treatment of advanced ovarian cancer. Br J Cancer 1990, 61, 495-496.
34. McGuire WP, Rowinsky EK. Old drugs revisited. New drugs and experimental approaches in ovarian cancer. Semin Oncol 1991, 18, 255-269.
35. Edmonson JH, McCormack GM, Wieand HS, et al. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma. A comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989, 81, 1500-1504.
36. Conte PF, Bruzzone M, Carnino F, et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1991, 9, 658-663.
37. Alberts DS, Green S, Hannigan EW, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992, 10, 706-711.
38. Swenerton K, Jeffrey J, Stewart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992, 10, 718-726.
39. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991, 9, 1668-1674.
40. Hacker NF, Berek JC. Cytoreductive surgery in ovarian cancer. In Alberts PS, Surwit EA, eds. Ovarian Cancer. Boston, Martinus Nijhoff, 1986, 53-67.
41. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. NCI Monogr 1975, 42, 101-104.
42. Copeland LJ, Gersherson DM, Wharton JT, et al. Microscopic disease at second look laparatomy in advanced ovarian cancer. Cancer 1985, 55, 472-476.
43. Ho AG, Beller U, Speyer JL, Colombo N, Wernz J, Beckman EM. A reassessment of the role of second-look laparatomy in advanced ovarian cancer. J Clin Oncol 1987, 5 (suppl.), 1316-1321.
44. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Long-term survival in ovarian cancer. Eur J Cancer 1991, 27, 1367-1372.
45. Hoskins PJ, O'Reilly SE, Swenerton KD, et al. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992, 10, 1561-1568.
46. Van Houwelingen JC, ten Bokkel Huinink WW, van der Burg MEL, et al. Predicatability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989, 7, 769-773.
47. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma. The Gynaecologic Oncology Group experience. J Clin Oncol 1991, 9, 1138-1150.
48. Witshaw E, Evans BD, Jones AC, Baker JW, Calver AH. JM8, successor to cisplatin in advanced ovarian carcinoma? Lancet 1983, 1, 587.
49. Calvert AH, Newell DR, Gumbrell LA. Carboplatin dosage: prospective evaluation of a simple formula on renal function. J Clin Oncol 1989, 7, 1748-1756.
50. Ozols RF, Hamilton TC, Hoskins WJ, Bast RC Jr, Young RC. Summary of symposium: biology and therapy of ovarian cancer. Semin Oncol 1991, 18, 297-306.
51. Ngan HY, Choo YC, Cheung M, et al. A randomized study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group chemotherapy 1989, 35, 221-227.